title: Steady-state and dynamic MR angiography with MS-325: initial experience in humans.
abstract: OBJECTIVE
  To evaluate the imaging performance and patient tolerance of a blood-pool contrast agent (MS-325) for magnetic resonance (MR) angiography.
  
  
  METHODS
  Imaging of peripheral and carotid vessels was performed in seven healthy volunteers in a phase I clinical trial of the gadolinium chelate MS-325. Each volunteer received an intravenous injection of 0.05 mmol/kg MS-325 over 30 seconds. Dynamic (arterial phase) and steady-state (arterial-venous phase) three-dimensional gradient-echo MR angiograms were acquired during, immediately after, and approximately 50 minutes after injection. Images were ranked (1 [poor] to 5 [excellent]) for overall image quality, and signal-to-noise ratio (S/N) and contrast-to-noise ratio (C/N) were measured by using standard techniques.
  
  
  RESULTS
  All volunteers tolerated the procedure well. The MS-325-enhanced studies demonstrated intense vascular signal. Mean peripheral arterial C/N was 12.9 +/- 4.8 (standard deviation), 78.8 +/- 29.4, 46.1 +/- 10.9, and 41.9 +/- 14.1 for the two-dimensional (2D) time-of-flight (TOF) and the contrast material-enhanced dynamic, early steady-state, and late steady-state images, respectively. Image quality of steady-state postcontrast images was statistically significantly (P < .02) higher than that of 2D TOF images. Image quality of early and late postcontrast images was similar, but a small (10%) decrease in C/N was noted from early to late images.
  
  
  CONCLUSIONS
  MS-325 provides excellent vascular and selective arterial enhancement during dynamic MR angiography. The long blood residence time also allows acquisition of steady-state images of the arteries and veins with excellent spatial resolution.
authors.affiliation: Department of Radiology, University of Wisconsin-Madison 53792-3252, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Grist
authors.forename: F R
authors.initials: FR
authors.lastname: Korosec
authors.forename: D C
authors.initials: DC
authors.lastname: Peters
authors.forename: S
authors.initials: S
authors.lastname: Witte
authors.forename: R C
authors.initials: RC
authors.lastname: Walovitch
authors.forename: R P
authors.initials: RP
authors.lastname: Dolan
authors.forename: W E
authors.initials: WE
authors.lastname: Bridson
authors.forename: E K
authors.initials: EK
authors.lastname: Yucel
authors.forename: C A
authors.initials: CA
authors.lastname: Mistretta
mesh_terms: D000005:Abdomen / Q000098:blood supply; D000328:Adult; D001158:Arteries / Q000033:anatomy & histology; D002339:Carotid Arteries / Q000033:anatomy & histology; D002614:Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects; D015331:Cohort Studies; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D007275:Injections, Intravenous; D007866:Leg / Q000098:blood supply; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010292:Paresthesia / Q000139:chemically induced; D012449:Safety; D013848:Thigh / Q000098:blood supply; D013997:Time Factors; D014680:Veins / Q000033:anatomy & histology
chemical_list: D002614:Chelating Agents; D003287:Contrast Media; D009942:Organometallic Compounds; D005682:Gadolinium; C109932:gadofosveset trisodium